Upstream Bio (UPB) Competitors

$6.69 -0.28 (-4.02%)

As of 01:37 PM Eastern

UPB vs. VIR, MAZE, TYRA, JBIO, and ORIC

Should you buy Upstream Bio stock or one of its competitors? Upstream Bio's main competitors and comparable companies include Vir Biotechnology (VIR), Maze Therapeutics (MAZE), Tyra Biosciences (TYRA), Jade Biosciences (JBIO), and Oric Pharmaceuticals (ORIC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Upstream Bio compare to Vir Biotechnology?

Vir Biotechnology (NASDAQ:VIR) and Upstream Bio (NASDAQ:UPB) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, risk, valuation, profitability and analyst recommendations.

65.3% of Vir Biotechnology shares are owned by institutional investors. 2.9% of Vir Biotechnology shares are owned by company insiders. Comparatively, 16.5% of Upstream Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Vir Biotechnology has a net margin of -638.88% compared to Upstream Bio's net margin of -4,955.67%. Vir Biotechnology's return on equity of -29.99% beat Upstream Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vir Biotechnology	-638.88%	-29.99%	-23.62%
Upstream Bio	-4,955.67%	-48.40%	-46.57%

Vir Biotechnology has a beta of 1.66, suggesting that its share price is 66% more volatile than the broader market. Comparatively, Upstream Bio has a beta of 1.26, suggesting that its share price is 26% more volatile than the broader market.

Vir Biotechnology currently has a consensus target price of $20.63, indicating a potential upside of 109.28%. Upstream Bio has a consensus target price of $29.67, indicating a potential upside of 343.45%. Given Upstream Bio's higher probable upside, analysts clearly believe Upstream Bio is more favorable than Vir Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Upstream Bio	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Upstream Bio has lower revenue, but higher earnings than Vir Biotechnology. Vir Biotechnology is trading at a lower price-to-earnings ratio than Upstream Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vir Biotechnology	$302.59M	5.51	-$437.99M	-$1.86	N/A
Upstream Bio	$2.85M	128.57	-$143.44M	-$2.90	N/A

In the previous week, Vir Biotechnology had 2 more articles in the media than Upstream Bio. MarketBeat recorded 2 mentions for Vir Biotechnology and 0 mentions for Upstream Bio. Vir Biotechnology's average media sentiment score of 0.10 beat Upstream Bio's score of 0.00 indicating that Vir Biotechnology is being referred to more favorably in the media.

Company	Overall Sentiment
Vir Biotechnology	Neutral
Upstream Bio	Neutral

Summary

Vir Biotechnology beats Upstream Bio on 12 of the 17 factors compared between the two stocks.

How does Upstream Bio compare to Maze Therapeutics?

Upstream Bio (NASDAQ:UPB) and Maze Therapeutics (NASDAQ:MAZE) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, media sentiment, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.

Upstream Bio currently has a consensus target price of $29.67, indicating a potential upside of 343.45%. Maze Therapeutics has a consensus target price of $66.00, indicating a potential upside of 124.95%. Given Upstream Bio's higher possible upside, research analysts plainly believe Upstream Bio is more favorable than Maze Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Upstream Bio	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00

Maze Therapeutics has a net margin of 0.00% compared to Upstream Bio's net margin of -4,955.67%. Maze Therapeutics' return on equity of -34.94% beat Upstream Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Upstream Bio	-4,955.67%	-48.40%	-46.57%
Maze Therapeutics	N/A	-34.94%	-30.18%

Maze Therapeutics has higher revenue and earnings than Upstream Bio. Maze Therapeutics is trading at a lower price-to-earnings ratio than Upstream Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Upstream Bio	$2.85M	128.57	-$143.44M	-$2.90	N/A
Maze Therapeutics	$20M	81.49	-$131.12M	-$2.52	N/A

In the previous week, Maze Therapeutics had 3 more articles in the media than Upstream Bio. MarketBeat recorded 3 mentions for Maze Therapeutics and 0 mentions for Upstream Bio. Maze Therapeutics' average media sentiment score of 1.31 beat Upstream Bio's score of 0.00 indicating that Maze Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Upstream Bio	Neutral
Maze Therapeutics	Positive

Upstream Bio has a beta of 1.26, indicating that its stock price is 26% more volatile than the broader market. Comparatively, Maze Therapeutics has a beta of 2.21, indicating that its stock price is 121% more volatile than the broader market.

Summary

Maze Therapeutics beats Upstream Bio on 12 of the 15 factors compared between the two stocks.

How does Upstream Bio compare to Tyra Biosciences?

Upstream Bio (NASDAQ:UPB) and Tyra Biosciences (NASDAQ:TYRA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, media sentiment, profitability, dividends, earnings, risk and institutional ownership.

In the previous week, Tyra Biosciences had 2 more articles in the media than Upstream Bio. MarketBeat recorded 2 mentions for Tyra Biosciences and 0 mentions for Upstream Bio. Upstream Bio's average media sentiment score of 0.00 equaled Tyra Biosciences'average media sentiment score.

Company	Overall Sentiment
Upstream Bio	Neutral
Tyra Biosciences	Neutral

Tyra Biosciences has lower revenue, but higher earnings than Upstream Bio. Tyra Biosciences is trading at a lower price-to-earnings ratio than Upstream Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Upstream Bio	$2.85M	128.57	-$143.44M	-$2.90	N/A
Tyra Biosciences	N/A	N/A	-$119.95M	-$2.40	N/A

Upstream Bio currently has a consensus price target of $29.67, suggesting a potential upside of 343.45%. Tyra Biosciences has a consensus price target of $46.90, suggesting a potential upside of 78.43%. Given Upstream Bio's higher probable upside, equities research analysts plainly believe Upstream Bio is more favorable than Tyra Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Upstream Bio	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Tyra Biosciences	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87

Upstream Bio has a beta of 1.26, indicating that its share price is 26% more volatile than the broader market. Comparatively, Tyra Biosciences has a beta of 0.77, indicating that its share price is 23% less volatile than the broader market.

Tyra Biosciences has a net margin of 0.00% compared to Upstream Bio's net margin of -4,955.67%. Tyra Biosciences' return on equity of -46.39% beat Upstream Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Upstream Bio	-4,955.67%	-48.40%	-46.57%
Tyra Biosciences	N/A	-46.39%	-43.07%

84.1% of Tyra Biosciences shares are held by institutional investors. 16.5% of Upstream Bio shares are held by company insiders. Comparatively, 12.5% of Tyra Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Tyra Biosciences beats Upstream Bio on 10 of the 15 factors compared between the two stocks.

How does Upstream Bio compare to Jade Biosciences?

Upstream Bio (NASDAQ:UPB) and Jade Biosciences (NASDAQ:JBIO) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk.

Jade Biosciences has lower revenue, but higher earnings than Upstream Bio. Jade Biosciences is trading at a lower price-to-earnings ratio than Upstream Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Upstream Bio	$2.85M	128.57	-$143.44M	-$2.90	N/A
Jade Biosciences	N/A	N/A	-$127.41M	-$1.92	N/A

Jade Biosciences has a net margin of 0.00% compared to Upstream Bio's net margin of -4,955.67%. Upstream Bio's return on equity of -48.40% beat Jade Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Upstream Bio	-4,955.67%	-48.40%	-46.57%
Jade Biosciences	N/A	-49.11%	-45.62%

Upstream Bio has a beta of 1.26, meaning that its stock price is 26% more volatile than the broader market. Comparatively, Jade Biosciences has a beta of 1.49, meaning that its stock price is 49% more volatile than the broader market.

Upstream Bio currently has a consensus target price of $29.67, indicating a potential upside of 343.45%. Jade Biosciences has a consensus target price of $51.75, indicating a potential upside of 144.98%. Given Upstream Bio's higher probable upside, analysts plainly believe Upstream Bio is more favorable than Jade Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Upstream Bio	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Jade Biosciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90

In the previous week, Jade Biosciences had 2 more articles in the media than Upstream Bio. MarketBeat recorded 2 mentions for Jade Biosciences and 0 mentions for Upstream Bio. Jade Biosciences' average media sentiment score of 1.45 beat Upstream Bio's score of 0.00 indicating that Jade Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Upstream Bio	Neutral
Jade Biosciences	Positive

Summary

Jade Biosciences beats Upstream Bio on 10 of the 14 factors compared between the two stocks.

How does Upstream Bio compare to Oric Pharmaceuticals?

Upstream Bio (NASDAQ:UPB) and Oric Pharmaceuticals (NASDAQ:ORIC) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and profitability.

Upstream Bio currently has a consensus target price of $29.67, indicating a potential upside of 343.45%. Oric Pharmaceuticals has a consensus target price of $19.45, indicating a potential upside of 39.56%. Given Upstream Bio's higher probable upside, research analysts clearly believe Upstream Bio is more favorable than Oric Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Upstream Bio	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Oric Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

Oric Pharmaceuticals has a net margin of 0.00% compared to Upstream Bio's net margin of -4,955.67%. Oric Pharmaceuticals' return on equity of -35.35% beat Upstream Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Upstream Bio	-4,955.67%	-48.40%	-46.57%
Oric Pharmaceuticals	N/A	-35.35%	-33.39%

95.1% of Oric Pharmaceuticals shares are held by institutional investors. 16.5% of Upstream Bio shares are held by insiders. Comparatively, 5.7% of Oric Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Oric Pharmaceuticals had 3 more articles in the media than Upstream Bio. MarketBeat recorded 3 mentions for Oric Pharmaceuticals and 0 mentions for Upstream Bio. Oric Pharmaceuticals' average media sentiment score of 1.14 beat Upstream Bio's score of 0.00 indicating that Oric Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Upstream Bio	Neutral
Oric Pharmaceuticals	Positive

Oric Pharmaceuticals has lower revenue, but higher earnings than Upstream Bio. Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than Upstream Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Upstream Bio	$2.85M	128.57	-$143.44M	-$2.90	N/A
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.35	N/A

Upstream Bio has a beta of 1.26, suggesting that its share price is 26% more volatile than the broader market. Comparatively, Oric Pharmaceuticals has a beta of 1.02, suggesting that its share price is 2% more volatile than the broader market.

Summary

Oric Pharmaceuticals beats Upstream Bio on 10 of the 15 factors compared between the two stocks.

Get Upstream Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding UPB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

UPB vs. The Competition

Export

Metric	Upstream Bio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$366.14M	$3.98B	$7.28B	$12.75B
Dividend Yield	N/A	3.64%	2.54%	10.79%
P/E Ratio	-2.31	11.63	271.35	24.10
Price / Sales	128.57	1,302.16	606.04	78.14
Price / Cash	N/A	44.94	29.03	36.90
Price / Book	1.06	17.24	11.19	6.40
Net Income	-$143.44M	-$22.72M	$3.46B	$348.28M
7 Day Performance	-6.30%	2.94%	2.06%	1.17%
1 Month Performance	4.37%	9.84%	7.42%	5.34%
1 Year Performance	-62.05%	54.50%	24.67%	16.25%

Upstream Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
UPB Upstream Bio	1.498 of 5 stars	$6.69 -4.0%	$29.67 +343.4%	-60.5%	$366.14M	$2.85M	N/A	38
VIR Vir Biotechnology	2.0643 of 5 stars	$9.49 +1.1%	$20.63 +117.3%	+113.5%	$1.56B	$68.56M	N/A	580
MAZE Maze Therapeutics	2.1351 of 5 stars	$29.13 +4.2%	$66.00 +126.6%	+118.2%	$1.51B	$167.50M	N/A	121	Positive News
TYRA Tyra Biosciences	1.9694 of 5 stars	$26.04 -0.7%	$46.90 +80.1%	+122.5%	$1.51B	N/A	N/A	20
JBIO Jade Biosciences	2.3973 of 5 stars	$23.55 +0.4%	$51.75 +119.7%	+159.3%	$1.49B	N/A	N/A	20

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:UPB) was last updated on 8/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Upstream Bio (UPB) Competitors

UPB vs. VIR, MAZE, TYRA, JBIO, and ORIC

How does Upstream Bio compare to Vir Biotechnology?

Summary

How does Upstream Bio compare to Maze Therapeutics?

Summary

How does Upstream Bio compare to Tyra Biosciences?

Summary

How does Upstream Bio compare to Jade Biosciences?

Summary

How does Upstream Bio compare to Oric Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UPB vs. The Competition

Upstream Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Upstream Bio (UPB) Competitors

UPB vs. VIR, MAZE, TYRA, JBIO, and ORIC

How does Upstream Bio compare to Vir Biotechnology?

Do institutionals & insiders have more ownership in VIR or UPB?

Is VIR or UPB more profitable?

Which has more risk & volatility, VIR or UPB?

Do analysts rate VIR or UPB?

Which has better earnings & valuation, VIR or UPB?

Does the media refer more to VIR or UPB?

Summary

How does Upstream Bio compare to Maze Therapeutics?

Do analysts rate UPB or MAZE?

Is UPB or MAZE more profitable?

Which has stronger earnings & valuation, UPB or MAZE?

Does the media refer more to UPB or MAZE?

Which has more volatility & risk, UPB or MAZE?

Summary

How does Upstream Bio compare to Tyra Biosciences?

Does the media refer more to UPB or TYRA?

Which has stronger valuation and earnings, UPB or TYRA?

Do analysts prefer UPB or TYRA?

Which has more volatility and risk, UPB or TYRA?

Is UPB or TYRA more profitable?

Do institutionals and insiders hold more shares of UPB or TYRA?

Summary

How does Upstream Bio compare to Jade Biosciences?

Which has higher valuation and earnings, UPB or JBIO?

Is UPB or JBIO more profitable?

Which has more risk and volatility, UPB or JBIO?

Do analysts recommend UPB or JBIO?

Does the media favor UPB or JBIO?

Summary

How does Upstream Bio compare to Oric Pharmaceuticals?

Do analysts recommend UPB or ORIC?

Is UPB or ORIC more profitable?

Do institutionals and insiders believe in UPB or ORIC?

Does the media refer more to UPB or ORIC?

Which has higher earnings and valuation, UPB or ORIC?

Which has more volatility & risk, UPB or ORIC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UPB vs. The Competition

Upstream Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools